Esperion Reports 144% Revenue Surge to $168.4M, Agrees to Acquire Corstasis
Esperion reported Q4 EPS of $0.21, short of estimates by $0.02, while revenue rose 144% to $168.4 million. The company agreed to acquire Corstasis Therapeutics to broaden its cardiovascular portfolio despite a negative enterprise value to operating cash flow ratio of -6.27.
1. Q4 Financial Performance
Esperion reported fourth-quarter 2025 EPS of $0.21, missing estimates by $0.02, while revenue climbed 144% year-over-year to $168.4 million, driven by U.S. net product revenue growth of 38%.
2. Corstasis Acquisition
The company entered into an agreement to acquire Corstasis Therapeutics, adding the bumetanide nasal spray Enbumyst to its cardiovascular pipeline to bolster treatment options for LDL-C management.
3. Cash Flow and Valuation
Despite strong top-line growth, Esperion’s enterprise value to operating cash flow ratio stands at -6.27, highlighting ongoing challenges in converting revenue into positive cash flow.